Tekla Life Sciences Investors
HQL · NYSE
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | – | $18,199 | $1,915 | $2,065 |
| % Growth | – | 850.5% | -7.3% | – |
| Cost of Goods Sold | – | $2,527 | $0 | $0 |
| Gross Profit | – | $0 | $1,915 | $2,065 |
| % Margin | – | 0% | 100% | 100% |
| R&D Expenses | – | $0 | $0 | $0 |
| G&A Expenses | – | $0 | $3,165 | $2,710 |
| SG&A Expenses | – | $0 | $3,182 | $2,719 |
| Sales & Mktg Exp. | – | $0 | $16 | $8 |
| Other Operating Expenses | – | $0 | $0 | $0 |
| Operating Expenses | – | $0 | $3,182 | $2,719 |
| Operating Income | – | -$47,234 | -$1,267 | -$653 |
| % Margin | – | -259.5% | -66.2% | -31.6% |
| Other Income/Exp. Net | – | $0 | $36,307 | $50,910 |
| Pre-Tax Income | – | -$47,234 | $35,040 | $50,256 |
| Tax Expense | – | $0 | $0 | $0 |
| Net Income | – | -$47,234 | $35,040 | $50,256 |
| % Margin | – | -259.5% | 1,830% | 2,433.4% |
| EPS | – | -1.64 | 1.22 | 1.84 |
| % Growth | – | -234.4% | -33.7% | – |
| EPS Diluted | – | -1.64 | 1.22 | 1.84 |
| Weighted Avg Shares Out | – | 28,872 | 28,772 | 27,351 |
| Weighted Avg Shares Out Dil | – | 28,872 | 28,772 | 27,351 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | – | $0 | $1,267 | $653 |
| EBITDA | – | -$47,234 | $0 | $101,166 |
| % Margin | – | -259.5% | 0% | 4,898.5% |